---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-004446"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:16:44.762067+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Guardant Health reports preliminary 2023 revenue ~$562-563M (+25% YoY); clinical test volumes up 39%

## Summary
- Full year 2023 revenue $562-563M, up 25% YoY; clinical test volume 172,900 (+39%).
- Q4 2023 revenue $153-154M (+21%); clinical tests 46,400 (+29%).
- Full year free cash flow approx. -$347M; cash and equivalents $1.2B as of Dec 31, 2023.
- Co-CEOs cite Shield blood test progress; expect FDA approval and IVD launch in 2024.
- Results are preliminary and unaudited; final audited results expected in February 2024.

## SEC filing metadata
- accession: 0001193125-24-004446
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/0001193125-24-004446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/d710991d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-004446
- JSON: https://secwatch.observer/filing/0001193125-24-004446.json
- Plain text: https://secwatch.observer/filing/0001193125-24-004446.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. reported the twelve-month period ended December 31, 2023 results: revenue $562 million and $563 million.
  - Period: the twelve-month period ended December 31, 2023
  - Revenue: $562 million and $563 million
  - Result: preliminary results
  source text: Full year 2023 preliminary unaudited financial results For the twelve-month period ended December 31, 2023, as compared to the same period of 2022: • Revenue of between $562 million and $563 million, an increase of 25%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/0001193125-24-004446-index.htm
- Earnings Releases
  Guardant Health, Inc. reported the three-month period ended December 31, 2023 results: revenue $153 million and $154 million.
  - Period: the three-month period ended December 31, 2023
  - Revenue: $153 million and $154 million
  - Result: preliminary results
  source text: Fourth quarter 2023 preliminary unaudited financial results For the three-month period ended December 31, 2023, as compared to the same period of 2022: • Revenue of between $153 million and $154 million, an increase of 21%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/0001193125-24-004446-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.